Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Fox

Showing results (131-140 of 133) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 133 results.
Investigational New Drugs|February 1, 2017
Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase IIC M Nijenhuis, L Lucas, H Rosing, et al.
Leukemia|July 16, 2011
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemiaJ E Lancet, F Ravandi, R M Ricklis, et al.
Nature Medicine|April 3, 2001
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versionsD Lawrence, Z Shahrokh, S Marsters, et al.
Pageof 14

Showing results (131-140 of 133) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 133 results.
Investigational New Drugs|February 1, 2017
Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase IIC M Nijenhuis, L Lucas, H Rosing, et al.
Leukemia|July 16, 2011
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemiaJ E Lancet, F Ravandi, R M Ricklis, et al.
Nature Medicine|April 3, 2001
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versionsD Lawrence, Z Shahrokh, S Marsters, et al.
Pageof 14